
Ozempic Lawsuit Targets Novo Nordisk Failure to Warn
Ozempic Lawsuit Targets Novo Nordisk Failure to Warn
On July 2, Geoffrey Symonds filed an Ozempic lawsuit that accused Novo Nordisk of failing to warn consumers of the risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which has been associated with the drug. Symonds v. Novo Nordisk alleges that Symonds...
www.lawyersandsettlements.com
Trenton, NJOn July 2, Geoffrey Symonds filed an Ozempic lawsuit that accused Novo Nordisk of failing to warn consumers of the risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), which has been associated with the drug. Symonds v. Novo Nordisk alleges that Symonds lost 85 percent of the vision in his left eye because of taking Ozempic for three months from November 2021 to January 2022. It was very sudden; it’s also irreversible. Symonds now has trouble managing his life.





